Advertisement

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Pharmaceuticals

GSK reports positive antibiotic trial results

by Rick Mullin
November 20, 2022 | A version of this story appeared in Volume 100, Issue 41

 

GSK says a Phase 2a clinical study shows its antitubercular drug candidate GSK3036656 was well tolerated and demonstrated early bactericidal activity in a 14-day test involving people with drug-susceptible pulmonary tuberculosis. The drugmaker also says it will stop enrollment, following positive results, in two Phase 3 trials of gepotidacin, a candidate to treat urinary tract infection in female adults and adolescents. GSK says it will seek US Food and Drug Administration approval.

Article:

This article has been sent to the following recipient:

0 /1 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.